Redeye: Orphazyme - Summary of 2018, important year ahead
Arimoclomol in the NPC indication will drive the story in the near-term but Orphazyme has a broad pipeline with multiple potential value drivers in the longer term. In this update we go through the recent news items and look ahead at the next steps for the company.
Read more and download the latest research report: http://bit.ly/2XBXEu8
Start following companies at Redeye to recieve the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/